2023 Annual Meeting | C132 - Controversies in Stroke Treatment and Prevention

Date Tuesday 04/25/23

Time 01:00 PM - 03:00 PM EST Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Pierre Fayad, MD, FAHA, FAAN

Topic(s) Cerebrovascular Disease and Interventional Neurology

Learning Objectives Participants should become familiar with areas in stroke treatment and prevention where evidence is lacking or insufficient to formulate clear recommendations, or where new evidence has emerged that challenges the current consensus. The course will address thoroughly a selected group of such controversial areas, that have not been covered in this previous course, and provide attendees with practical approaches to help them sort through such situations.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice, Quality Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student, Business Administrator

Teaching Styles Didactic, Audience Participation

Event Timeline
01:00 PM - 01:05 PM EST	Introduction	Overview of Session Pierre Fayad, MD, FAHA, FAAN
01:05 PM - 01:35 PM EST	Speaker	Controversies in the Diagnosis and Management of Intracerebral Hemorrhage Steven M. Greenberg, MD, PhD, FAAN
01:35 PM - 02:05 PM EST	Speaker	Controversies in the Management of Hyperlipidemia For Stroke Prevention Larry B. Goldstein, MD, FAHA, FAAN
02:05 PM - 02:35 PM EST	Speaker	Controversies in Anti-Thrombotic Therapy for Acute Stroke and Prevention Pierre Fayad, MD, FAHA, FAAN
02:35 PM - 03:00 PM EST	Discussion	Panel Discussion and Questions and Answers Pierre Fayad, MD, FAHA, FAAN, Steven M. Greenberg, MD, PhD, FAAN, Larry B. Goldstein, MD, FAHA, FAAN

Faculty Disclosures
Larry B. Goldstein, MD, FAHA, FAAN	The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from Janssen. Dr. Goldstein has received publishing royalties from a publication relating to health care.
Pierre Fayad, MD, FAHA, FAAN	Dr. Fayad has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Fayad has received personal compensation in the range of $0-$499 for serving as a Member Data Safety & Monitoring Committee with NINDS.
Steven M. Greenberg, MD, PhD, FAAN	Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squib. The institution of Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Greenberg has received research support from National Institutes of Health. Dr. Greenberg has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��